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Introduction
Since the birth of the first child after ovarian tissue transplan-
tation, fertility protection in women and men has developed 
into a new and clinically relevant independent field.1 This field 
has a number of special features.
On one hand, the discipline is interdisciplinary, since fertil-
ity protection requires close coordination between reproductive 
medicine specialists, reproductive biologists, and oncologists in 
various disciplines.
On the other hand, some fertility-preserving measures such 
as transplantation of ovarian tissue, in vitro maturation of 
oocytes, maturation of oocytes from ovarian tissue, and the 
cryopreservation of testicular tissue from prepubertal boys are 
still in clinical or even scientific development and therefore 
require a high degree of specialisation on the part of the centres 
involved.2-5
In addition, this new specialist field represents a particular 
health policy challenge, since fertility-protection measures 
are to be understood as a treatment for side effects of gonado-
toxic treatments and would therefore normally have to be 
reimbursed by health insurance companies, which is not yet 
the case in many countries.
Due to these special features of this field, it is inevitable that 
all the scientific, clinical, and, if necessary, even health care 
policy areas involved organise themselves into a network struc-
ture both as a medical-logistic network and as a professional 
medical society.
The necessary network structures can differ significantly at 
regional, national, and international level, as the size of the 
regions to be integrated and the local cultural and geographical 
conditions, as well as the political conditions are very different.
Therefore, in this article, we would like to point the basic 
importance and the chances, but also the difficulties, of fertil-
ity-protection networks and give practical guidance for the 
development of such network structures. We will not only dis-
cuss network structures theoretically but also present them 
based on three established different sized networks. These 
three networks have different goals and different logistic struc-
tures and thus cover the possible range of possible network 
structures.
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The selected networks are as follows:
1. The Danish Network (www.rigshospitalet.dk). This 
network is a centralised network for the practical imple-
mentation of specific fertility-preserving techniques 
such as the cryopreservation and transplantation of 
ovarian tissue in a small country.
2. The German-Austrian-Swiss network FertiPROTEKT 
(www.fertiprotekt.com). This network is a centralised as 
well as decentralised network that controls the imple-
mentation of fertility-protective techniques in a large 
country.
3. The Oncofertility Consortium (www.oncofertility.
northwestern.edu). This is a decentralised, internation-
ally oriented network that primarily serves the transfer 
of knowledge among its members.
Network Structure
The structure of a network depends on the following mostly 
given and therefore unchangeable conditions and the self-
imposed goals:
Given conditions for the establishment of a network
Size of the region to be networked.
Transport-logistical development of the region.
Density and area coverage of reproductive medicine cen-
tres.
Willingness of the centres and doctors to cooperate
Political and financial support.
Health care policy conditions.
These conditions are largely unchangeable. Accordingly, the 
desired network structures must take these conditions into 
account and integrate them into the network concepts.
Goals for the establishment of a network
A nationwide supply with specialised centres should be 
established.
Individual, especially not yet fully established or experi-
mental reproductive techniques such as cryopreservation 
and transplantation of ovarian tissue and cryopreserva-
tion of testicular tissue from prepubertal boys should be 
centralised.
Regular information events should be carried out by the 
participating centres and associated disciplines.
A data register is to be established.
The establishment of a good regional or national network 
should try to achieve all these goals. Only partial implementa-
tion is possible in some regions and countries.
Structural composition of networks
Networks are often modular; the number of modules depends 
on their size (Figure 1).
The conditions and intentions of these modules are differ-
ent (Table 1). The smallest modular unit is usually a reproduc-
tive medicine centre or a clinic that networks regionally or 
within the clinic with oncologists. Patients are referred to the 
reproductive medicine centres directly by the oncologists. The 
therapy decision is often based on direct bilateral communica-
tion. The reproductive medicine centre documents the treat-
ments so that the data can later be passed on to a registry.
The next medium-sized modular stage is a union of local 
units into a small national or large regional network. An exam-
ple of such a network is Denmark (www.rigshospitalet.dk). 
The centres know each other, and personal communication is 
possible. Data from the local units are merged into a register, 
which is relatively easy to create due to its limited size. It is eas-
ily possible to establish centralised, highly specialised facilities, 
for example, cryopreservation of gonadal tissue. The establish-
ment of such centralised facilities allows high-quality fertility-
protective techniques, scientific evaluation, good transparency 
of activities, and thus also health care policy initiatives. Due to 
short travel distances, shorter training courses can be organised 
with the help of oncologists. The strengths of these medium-
sized networks lie in the possibility of being able to collect 
high-quality data, as detailed data documentation is usually 
possible.
Figure 1. Networks are frequently set up as multimodular structures. 
Small modules (blue) such as infertility centres or hospitals integrate 
gynaecologists and oncologists etc. (green). Several of these small 
modules (blue) are organised as a medium-sized network (orange) such 
as regional or small national networks. Several of these medium-sized 
modules (orange) are organised as a large network with a centralised 
body (red) which organises registries, scientific activities, conferences, 
and so on.
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In very large regions or larger countries, several network 
structures are combined into one large network. One such 
example is the FertiPROTEKT network (www.fertiprotekt.
com). Accordingly, there may be several central cryopreser-
vation facilities. Continuing education takes place every 1 to 
2 years, mainly with reproductive physicians and biologists, 
but less with oncologists. These are usually spread over 1 to 
2 days because of the longer travelling distances. A register 
requires good and easy-to-use online input tools to ensure 
reliable data entry. The strength of these large networks lies 
in their ability to collect relevant amounts of data. The level 
of detail of this data is limited by online data collection.
In addition, it is possible to combine several of these net-
works for data collection and professional exchange. Examples 
of such international networks are the ‘Oncofertility® 
Consortium’ (www.oncofertility.northwestern.edu), the Special 
Interest Group ‘Fertility Preservation’ of the European Society 
of Human Reproduction and Embryology (ESHRE) (www.
eshre.eu/Specialty-groups/Special-Interest-Groups/Fertility-
Preservation.aspx), and the ‘International Society for Fertility 
Preservation’ (ISFP) (www.isfp-fertility.org).
Obstacles to Creating Networks
The explanations have shown that networks are clinically, sci-
entifically, and politically of great importance. In practice, how-
ever, they are often difficult to implement.
What are the reasons for this?
In most cases, networks can only be implemented in regions 
and countries that have good medical, technical, and infra-
structure care. Thus, the topic of fertility protection can only be 
of importance if sufficient oncological care is guaranteed. If 
these requirements are not met, network-based care with fertil-
ity-protective measures is hardly possible.
In industrialised, well-developed countries, there are no 
infrastructural obstacles to the establishment of networks. 
Nevertheless, it is often difficult to build networks. The main 
obstacle is the ‘human factor’ (Table 2).
When setting up a network, priority should be given to 
examining what can motivate active participation. University 
centres are often more interested in scientific activities and 
cooperation, private centres more in economic advantages, and 
the use of networks as an advertising platform. Possible moti-
vations for active participation must be identified and inte-
grated into the network programmes. The willingness to 
participate in the network can often be increased by a demo-
cratic voice. If there is a danger that the right to have a say in 
the network will hamper its development, a democratically 
elected network board can also make sense to promote the 
development and expansion in a targeted manner with a small 
group of board members.
Financing of Networks
The financing of networks differs regionally and nationally. 
The start-up financing for setting up a network may differ.
Only a few thousand Euros were initially available from a 
pharmaceutical company for the FertiPROTEKT network to 
set up a website. All other costs were covered by the members. 
Annual continuing education was covered by pharmaceutical 
companies and participation fees. All other activities were ini-
tially performed voluntarily.
In contrast, the United States initially made 22 million 
dollars available for the founding of the Oncofertility 
Consortium.
Undoubtedly, generous start-up financing is advantageous 
for the establishment of a network. Far more decisive is not the 
amount of funding but the initiative and willingness of a few 
people.
The following are necessary to start a network:
•• An initiation meeting with as many reproductive medi-
cine centres as possible.
•• The development of a network name and logo.
•• A website that can be created largely free of charge by 
network members with IT experience.
Table 1. Characteristics of the different sized networks.
CHARACTERISTICS LoCAL AND 
REGIoNAL 
NETWoRKS
SMALL NATIoNAL 
oR NATIoNWIDE 
NETWoRKS
LARGE NATIoNAL 
NETWoRKS
VERY LARGE 
NETWoRKS oR 
CoNTINENTAL 
NETWoRKS
Example Reproductive 
medicine centre or 
clinic
Danish network  
(www.rigshospitalet.dk)
FertiPRoTEKT  
(www.fertiprotekt.com)
oncofertility Consortium 
(www.oncofertility.
northwestern.edu)
Centralization of 
facilities (eg storage of 
gonadal tissue)
Yes Yes, mostly one facility Yes, mostly several facilities Rather no
Continuing education Bilateral exchange Continuing education National congresses International congresses
Data collection in 
registers
Very possible Quite possible, high data 
quality
Possible, lower data quality, 
but high data quantity
Possible to a limited 
extent
Political activities Not as good Good Good Not as good
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•• An online documentation tool which can be created 
largely free of charge by network members with IT 
experience.
•• Regular (eg annual) continuing education events.
Introduction of the Danish Network – Centralised 
Network for Smaller Countries/Large Cities
History
Inspired by research efforts three decades ago from a large 
number of people including Roger Gosden, Outi Hovatta, 
Kutluk Oktay, and David Baird, it became clear that it would 
be potentially clinically feasible to freeze human ovarian tissue 
with the intention of replacing it later to restore ovarian func-
tion. At the end of the last century, encouraging results emerged 
from primate studies and from transplantation of human ovar-
ian tissue.6,7 This sparked the first clinical initiatives of freezing 
ovarian tissue in the United Kingdom and Belgium. In 
Denmark, our laboratory conducted a number of mouse stud-
ies, in which different cryoprotectants and freezing protocols 
were evaluated.8 However, Danish legislation clearly stated 
that it was illegal to transplant ovarian tissue to a woman. In 
1998, we had a direct correspondence with Danish Minister of 
Health and he concluded that there were no restrictions on 
freezing ovarian tissue from a woman as long as only autolo-
gous transplantation was considered. There was no time limit 
on the storage period and normal medical rules applied for use 
of this technique including replacement of frozen thawed tis-
sue. In addition, the Minister of Health informed that similar 
rules applied for testicular tissue. This was basically a very lib-
eral rule that placed this new technique in the context of nor-
mal medical practice and the concept of ‘do no harm’.
At the end of the last century, our own laboratory had a 
more than 40-year-old tradition for studying the physiology of 
and working with human ovaries as the only laboratory in 
Denmark focussing on female reproduction. We started out 
with a clinical service freezing ovarian tissue at our local 
hospital in 1999, and soon thereafter, other parts of Denmark 
also wanted to start. We shortly realised that it would be more 
effective if we could centralise this service, which at that time 
was only performed occasionally. Instead of doing few cases per 
centre, we reasoned that it would provide a better service if the 
activity was centralised to the laboratory in which the knowl-
edge and expertise of dealing the human ovaries was already 
available. On this background, we developed what is now 
known as the Danish concept for freezing ovarian tissue ‘the 
woman stays the tissue moves’ (Figures 2 and 3).9-12
Structure
Cancer treatment in Denmark is centralised mainly to three 
university hospitals located in different parts of Denmark. 
Each of these hospitals also has a fertility clinic which focus on 
in vitro fertilisation (IVF) treatment and other assisted repro-
ductive technology (ART) procedures. In addition, our net-
work now also includes Skåne Region of Sweden, in which the 
University Hospital of Lund and Malmø are members. These 
two regions have entered a formal agreement, allowing patients 
from one country to be treated in other country in the area of 
reproductive medicine. The Swedish side also has a fertility 
clinic that is coordinating the local counselling. The Skåne 
Region is now connected to Copenhagen via a bridge, and the 
transport time from the local hospital to the central laboratory 
is maximally 1 to 2 hours by car and lower from other parts of 
Denmark. Importantly, all these clinics are public-funded hos-
pitals, and patients receive treatment for free paid for by the 
taxes, including extraction of tissue, freezing, storage, and 
transplantation. Furthermore, if ART is needed after trans-
plantation, this will also be covered by the public health care 
system. Basically, any Danish woman or women in the Skåne 
Region of Sweden, who potentially may benefit from these 
procedures and who qualify for these treatments (ie age, diag-
nosis, and clinical evaluation) should have it offered and then it 
is her decision to accept or decline the offer.
Table 2. The human factor as the main obstacle in the establishment of networks.
oBSTACLES To 
ESTABLISHING NETWoRKS
WAYS To AVoID THESE oBSTACLES
Scientific competition • Consideration of all persons involved as co-authors in publications
Lack of time for documentation • High-quality documentation software
• Interfaces with already established national registers to avoid repeated entries
Lack of interest • Sensitisation to the fact that fertility-protective measures are also economically relevant
• Use of the network website as an advertising platform for member centres
• Democratic voice in decision-making processes
• Annual membership meetings at interesting locations with an interesting programme
• Introduction of certificates for member centres and their external presentation
Lack of awareness • Development of good websites and linking to member centres to increase Internet presence
• Regional and national information events
Lack of willingness to cooperate • Development of political activities to enforce cooperation
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In each of these fertility clinics, one or two consultants have 
specialised in fertility preservation. Patients potentially requiring 
fertility preservation identified in the oncological, haematologi-
cal, or other departments in which patients are exposed to poten-
tial gonadotoxic treatment are referred to the consultants of the 
fertility clinic where they immediately get a consultation. Here, 
the different options are discussed with the patient including 
ovarian stimulation with cryopreservation of mature oocytes, 
excision, and cryopreservation of ovarian tissue or doing nothing. 
Depending on the clinical evaluation and the patient’s wishes, a 
plan for fertility preservation is agreed upon. In case freezing of 
ovarian tissue is planned, a date will be agreed upon with the 
central laboratory performing the cryopreservation and the sur-
geons excising the ovarian tissue at the local hospital.
The surgical intervention to extract the tissue is normally 
the first operation on that day, and the tissue will be able to 
reach the central laboratory in maximally 4 to 5 hours. After 
excision of the ovarian tissue, the surgeon will bring it to the 
local laboratory, where the tissue is placed in a 50-ml tube with 
basal medium that goes into a flamingo-box filled with crushed 
ice to maintain temperatures around 0°C. The box is trans-
ported to the central laboratory that checks for the presence of 
ice and processes the tissue immediately after arrival.
After cryopreservation, the tissue will be stored at the cen-
tral laboratory and kept in liquid nitrogen until potential use or 
until the patient decides otherwise for her tissue. The central 
laboratory is accredited by the Danish authorities to conduct 
this treatment including a licence according to the European 
Union (EU) tissue directive. We have collaborated with the 
competent Danish authorities to formulate guidelines for new 
clinics and networks starting out to cryopreserved ovarian tis-
sue.13 If the patient request transplantation, the tissue will be 
transported in liquid nitrogen to the local hospital, where the 
surgical procedure of replacing the tissue will take place.
The clinical follow-up of transplanted patients is performed 
by the local hospital including monitoring of whether the 
patient becomes pregnant, experience relapse and so on.
Representatives from the participating clinics in the net-
work will meet to discuss the service and results to align poli-
cies and various other matters when needed. We are setting up 
a framework for a database containing all information on 
patients who have ovarian tissue cryopreserved, which will pro-
vide valuable information looking forward. The competent 
Danish authorities secure implementation of the EU tissue 
directive and also function as advisers to the political system. 
We have discussions with authorities and have direct political 
Figure 2. Number of cryopreservations of ovarian tissue per year in the collaborating centres covering all of Denmark and the very southern part of 
Sweden.
Figure 3. Yearly number of cryopreservations of ovarian tissue (grey bar) and number of transplantations of frozen/thawed ovarian tissue (black bar).
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contacts where we try to modify the Danish regulations to 
allow storage of tissue for social indications and for postponing 
menopause at the cost of the patient herself.
Financial support
Initially, the project was financed from external funding by the 
Danish Cancer Society, but around the last 10 years, the treat-
ment has been recognised as an established treatment that the 
public health care system covers. As the technique is almost 
exclusively performed in the public system of hospitals that 
accounts for more than 99% of activity in the medical field 
anyway, the patient categories who have this technique offered 
for free have been limited to patients with a risk of iatrogenic-
induced follicle loss and infertility plus patients with a genetic 
condition that may render them infertile prematurely.
Scientif ic focus
The scientific focus in Denmark has during recent years been 
on the surplus medulla tissue that contains growing follicles 
that do not sustain freezing (Table 3). Normally this tissue is 
discharged, but we have ethical permission to ask women for 
donation of this surplus tissue for research purposes. 
Furthermore, we can ask women who have cortical stored and 
who do not wish to continue storage for permission to use the 
tissue for research purposes. This has resulted in an unprece-
dented access to normal ovarian tissue both fresh and frozen 
from women at various ages and has allowed us to study human 
folliculogenesis.
Lately, we are focussing on establishing an optimised plat-
form for human in vitro maturation (IVM), since the surplus 
medulla tissue contains immature oocytes which may become a 
surplus fertility-preservation option in case metaphase II (MII) 
oocytes can be generated in sufficient numbers with sufficient 
quality. We are in the situation that IVM is not considered a 
standard procedure in Denmark, and we are legally unable to 
use the MII oocytes generated for clinical purposes.47
Key points for success of the network
The most important task of the network has been to establish 
a patient friendly and patient-oriented treatment offer that 
provided stable, reliable, and well-documented results in terms 
of follicle survival in connection with the freezing procedure 
and renewed and improved ovarian function after transplanta-
tion. Our service has provided these results to a large extent:
1. Following transplantation frozen/thawed ovarian tissue 
more than a total of 130 times; the tissue has consist-
ently provided renewed and improved ovarian function 
for variable time periods mainly depending on the initial 
follicular density, patient age, and amount of tissue 
transplanted. Except for one case, where a woman in her 
Table 3. Scientific focus and examples of corresponding 
publications with the participation of the Danish network.
SCIENTIFIC FoCUS ExAMPLES oF PUBLICATIoNS
•  New technologies, 
options, and issues of 
importance for fertility 
preservation and 
restoration
 • Andersen et al14
 • Schmidt et al15
 • Rosendahl et al16
 • Rosendahl et al17
 • Schmidt et al18
 • Andersen et al19
 • Donnez et al20
 • Andersen21
 • Andersen and Kristensen22
 • Kristensen et al23
 • Andersen et al13
 • Kristensen et al24
•  Human small antral 
follicles
 • Andersen and Byskov25
 • Andersen et al26
 • Nielsen et al27
 • Andersen et al28
 • Nielsen et al29
 • Jeppesen et al30
 • Jeppesen et al31
 • Jeppesen et al32
 • Kristensen et al24
•  In vitro follicle growth 
and follicle activation
 • Schmidt et al33
 • Meirow et al34
 • Yin et al35
 • Kristensen et al36
 • Kristensen et al37
•  Evaluation of potential 
malignant cell 
contamination in 
ovarian tissue
 • Rosendahl et al38
 • Rosendahl et al39
 • Andersen et al10
 • Greve et al40
 • Greve et al40
 • Dolmans et al41
 • Ernst et al42
 • Sørensen et al43
 • Andersen et al44
 • El Issaoui et al45
• In vitro maturation  • Wilken-Jensen et al46
 • Yin et al47
 • Gruhn et al48
•  Transplant tissue to 
restore reproductive 
and/or endocrine 
function
 • Schmidt et al49
 • Schmidt et al50
 • Rosendahl et al16
 • Andersen et al51
 • Ernst et al42
 • Greve et al52
 • Schmidt et al53
 • Greve et al54
 • Ernst et al55
 • Rosendahl et al56
 • Macklon et al57
 • Jensen et al11
 • Jensen et al58
 • Jensen et al59
 • Gellert et al60
 • Matthwes et al61
 • Lunding et al62
•  Cryopreservation and 
transport protocols do 
not affect tissue quality 
nor follicle growth
 • Schmidt et al15
 • Rosendahl et al8
 • Kristensen et al63
•  Human preantral 
follicles
 • Kristensen et al64
 • Markholt et al65
 • Kristensen et al66
 • Kristensen et al67
•  Patient attitudes and 
effect of cryopreserv-
ing one ovary
 • Schmidt et al68
 • Macklon et al69
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mid-thirties had only three pieces of cortical tissue fro-
zen, which did not result in ovarian function after 
transplantation.
2. It has been a focus area to employ a freezing technique 
with as good a follicular survival rate as possible. We 
have recently published a new quantitative method to 
evaluate follicular survival following a period of freezing 
and found a survival rate of on average 84%, with a 91% 
rate of healthy follicles in unfrozen control samples.70 
Furthermore, survival rates were constant over a period 
of freezing lasting 17 years and similar irrespective of 
whether the tissue was transported or not.
3. During several different interviews, patients have 
expressed great satisfaction with the treatment offer and 
the ability to stay in the local environment at difficult 
times having just faced a cancer diagnosis. The psycho-
logical impact of having tissue stored has a massive posi-
tive impact on many patients.
What can be further improved and further 
challenges
We have now recently documented that the quantitative sur-
vival of follicles during the freezing process is very high show-
ing that only a minor part of follicles is lost during the freezing 
process.70 In contrast, the follicle loss during transplantation 
due to poor vascularization, ischemia, and reduced oxygen ten-
sion accounts for the clear majority of follicle demise. We are 
therefore now trying to improve follicle survival during the ini-
tial stages of revascularization by interfering with the processes 
that lead to follicle atresia.
Furthermore, one aspect that can be optimised and which is 
of obvious importance for the patients is the speed at which 
fertility preservation is executed. They may suffer a potential 
deadly disease and require in many instances gonadotoxic 
treatment as fast as possible. We are now trying to monitor the 
speed at which the procedure is executed and whether there 
may be cases where we can reduce the time needed to perform 
the fertility-preservation procedure.
Introduction of FertiPROTEKT Network – a Partly 
Decentralised Network for Large Countries
History
At the start of this millennium, various scientific endeavours in 
the field of fertility protection already existed in Germany,71,72 
but there was still no coordinated counselling and care of 
patients. Therefore, at the initiative and invitation of Prof M. 
von Wolff (then Department of Gynaecological Endocrinology 
and Fertility Disorders, Heidelberg) and Prof M. Montag 
(then Department of Gynaecological Endocrinology and 
Reproductive Medicine, Bonn), 30 university reproductive 
medical centres met in Heidelberg in May 2006 and founded 
the FertiPROTEKT network. The members elected 
a leadership team for 2 years each, in which both physicians 
(representatives of university and non-university centres) and 
biologists were represented.73 Since 2008, private centres can 
also become members. The network now also includes centres 
from Austria and Switzerland (www.fertiprotekt.de, www.fer-
tiprotekt.ch, www.fertiprotekt.at, and www.fertiprotekt.com).
However, the increasingly well-known national and inter-
national network was initially not a founded scientific society 
and was in danger of, for example, being insufficiently recog-
nised and acknowledged in professional policy discussions or in 
the development of guidelines by other (including interdisci-
plinary) scientific societies. Therefore, in 2015, the decision 
was made to create a scientific society. The FertiPROTEKT 
Network e.V. was founded by the then management team on 
November 10, 2015, in Hamburg. The main office is in 
Germany (Marburg/Lahn).
Centres that would like to become members of the 
FertiPROTEKT network must prove with their application 
that they not only advise on fertility protection but that they 
can also implement all fertility-protective methods themselves 
or in established cooperations.
Structure
The FertiPROTEKT network comprises 125 centres. In 2017, 
1156 consultations and 848 documented fertility-protective 
therapies were performed (Figures 4 and 5).
The structural characteristics shown in Table 1 are repre-
sented as follows in the network FertiPROTEKT.
Centralisation of facilities. This applies to the centralization of 
cryobanks for ovarian tissue in the FertiPROTEKT network. 
Specialised cryobanks are associated with the university gynae-
cology clinics in Bonn, Düsseldorf, and Erlangen. There is no 
compulsory requirement for the member centres to send their 
samples to these cryobanks; however, they do so with great 
participation.
The cryobanks have established a transport logistics system 
which plans that the peripheral member centre providing 
advice and the indication for cryopreservation of ovarian tissue 
orders a special transport container from the cryobank and has 
it transported to the relevant centre. The latter sends the tissue 
immediately postoperatively in this container in a nutrient 
medium on ice (ie under defined conditions) to the cryobank 
overnight, where it is prepared and cryopreserved.
Continuing education. From 2006 to 2018, 2-day working 
meetings were held annually at different locations, organised 
logistically and in terms of content by the board of the net-
work and a representative of the member centre of each venue. 
In addition to individual lectures, the programme included 
workshops on various fertility-protection methods. From 
2018, these meetings will only be held every 2 years because 
FertiPROTEKT has since then been able to conduct scientific 
meetings on topics of its own choice at least once a year at 
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Figure 4. FertiPRoTEKT centres in Germany, Austria, and Switzerland.
their congress(es), thanks to its cooperation with other scien-
tific societies.
Data collection in registers. Data are currently entered in a self-
created register, which is accessible to the member centres via 
the intranet of the FertiPROTEKT homepage. These data are 
evaluated once a year and is presented to the members. From 
2019, FertiPROTEKT will cooperate with the German IVF 
Register (https://www.deutsches-ivf-register.de/), which has 
adapted its data collection and evaluation for this purpose. The 
FertiPROTEKT data will then be integrated into the so-called 
IVF Yearbook, in which the German IVF Register has pre-
sented the results of all German ART cycles for many years. 
FertiPROTEKT finances this cooperation including program-
ming work and so on via the Society’s account.
Political activities. FertiPROTEKT is a well-known and well-
networked contact partner for other scientific societies; patient 
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organisations including self-help groups or political parties 
due to its long-standing presence at congresses; many publica-
tions; and other scientific activities. The most important cur-
rent focus of political activities is efforts to enforce the 
financing of fertility-protective services by the health insur-
ance companies.
Financial support
When the FertiPROTEKT network was founded, only a few 
thousand Euros were available from a pharmaceutical company 
to set up a website. All other costs were covered by the mem-
bers. Annual continuing education was covered by pharmaceu-
tical companies and participation fees. All other activities were 
carried out on a voluntary basis.
Since the founding of the FertiPROTEKT Society, mem-
bership fees have been available which are charged annually per 
centre at a cost of 180 Euro. In addition, there are sponsoring 
members in the form of pharmaceutical companies who 
together pay 15 000 Euro annually. These revenues can be used 
to run an office and fund board meetings as well as a few net-
work activities. The website and the register will continue to be 
run by the members on a voluntary basis.
Scientif ic focus
The scientific strengths lie in register analyses, studies with tis-
sue stored in centralised cryobanks, smaller multicentre studies, 
and the compilation of practically oriented recommendations 
(Table 4).
Key points for success of the network
•• Establishment of numerous and qualified counselling 
and therapy centres
The greatest merit of the network is the consolidation and 
coordination of many advisory member centres, which helps 
patients and oncologists, to find a contact person for advice on 
fertility-protection measures even at short notice, who can also 
implement them promptly if they so wish.
•• Coordination of content of counselling and therapies
Through studies, publications of recommendations and 
joint exchange among member centres and other specialist 
areas, the network has created a basis for the content-related 
consultation and implementation of fertility-protection thera-
pies. The annual 2-day national member meetings, in which 
approximately 200 persons participate, are an essential element 
for the coordination of content.
•• Documentation of consultations and therapies in a register
A register for fertility-protective consultations and therapies 
has existed since 2007. Due to the high quantity of data and the 
further improvement in quality in the future (through data entry 
via the national IVF register), there have been and will be oppor-
tunities in the future to clarify scientific questions. In addition, 
the amount of data is an argumentation aid, for example, in the 
enforcement of cost absorption by health insurance funds.
•• Initiation, implementation, and support of studies
The close cooperation and common interests in the network 
enable a timely agreement on the initiation of studies and their 
implementation. Scientific questions from member centres can 
be dealt with conceptually within a short period of time and 
can be investigated by joint prospective or retrospective studies 
on larger amounts of data.
•• Definition of standards and publication of 
recommendations
Joint working meetings in combination with our own study 
data and international experience form the basis for the con-
stantly developing standards discussed in the network, as well 
Figure 5. Number of documented counsellings and treatments performed by the large German-Austrian-Swiss network FertiPRoTEKT.
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as published recommendations for counselling and therapy in 
the context of fertility protection. The first recommendations 
were published in 2011 with ‘online access’ to make them avail-
able to as many readers as possible free of charge.90 The update 
was carried out in 2018 with a paper on indications based on 
selected diseases and another on fertility-protective tech-
niques.91,92 The association also financed the online access for 
these two publications. A German Austrian and Swiss guide-
line on fertility preservation was prepared and published93 by 
the AWMF with the contribution of FertiPROTEKT. 
Furthermore, a practically orientated textbook on fertility pres-
ervation has been published by the FertiPROTEKT network. 
It is currently re-edited and will then not only be available in 
English but also in German.
What can be further improved and further 
challenges
At a strategy meeting in April 2018, the executive board of the 
FertiPROTEKT network intensively discussed topics includ-
ing cost absorption by health insurance funds, research, mar-
keting, contacts with national, and international scientific 
societies as well as the documentation of register data and 
developed a basis for concepts and solutions that will be 
implemented over the coming years. The main objectives are, 
on one hand, an even closer oncological link, for example, to 
oncological societies, to better coordinate the indications for 
counselling, and for the implementation of fertility-protective 
measures and, on the other hand, the implementation of cost 
reimbursement of fertility-protective measures by health 
insurance companies.
Introduction of the Oncofertility Consortium – A 
Decentralised Global Network
History
Oncofertility is a discipline that merges oncology with fertility 
and has moved rapidly from the purview of individual champi-
ons to an integrated field that has become standard of care in 
many institutions.94 Oncofertility as a field has developed in 
parallel to the many life-preserving advances in oncologic care, 
including earlier diagnostics and the emergence of targeted 
cancer therapies, methods to reduce radiation dose and field, 
and localised surgical procedures. Addressing the complex 
treatment plans, general health, and quality of life issues that 
concern young cancer patients whose fertility may be threat-
ened by their disease or its treatment is a priority, and the 
Oncofertility Consortium has led efforts in this area for almost 
15 years.94-104 Northwestern University was first funded as a 
Specialised Cooperative Centre Programme in Reproductive 
Research (SCCPIR) in 2003, and the Centre for Reproductive 
Research focused on understanding structure-function rela-
tionships in reproductive science. This centre provided a mech-
anism to bring new perspectives to reproductive science from 
ancillary disciplines (eg bioengineering and structure biology). 
In 2007, we transitioned this fundamental science to a National 
Institutes of Health (NIH) Roadmap Interdisciplinary 
Research Consortium – the Oncofertility Consortium – to 
Table 4. Scientific focus and examples of corresponding publications with the participation of the FertiPRoTEKT network.
SCIENTIFIC FoCUS ExAMPLES oF PUBLICATIoNS*
• Efficacy of luteal phase and random-start ovarian stimulation  • von Wolff et al74
 • von Wolff et al75
• Effectiveness of ovarian stimulation with various concurrent diseases  • Henes et al76
 • Henes et al77
 • Henes et al78
 • von Wolff et al79
• Transport and transplantation of ovarian tissue  • Dittrich et al80
 • Dittrich et al81
 • Van der Ven et al2
 • Liebenthron et al82
 • von Wolff et al83
• Combination of ovarian tissue cryopreservation and ovarian stimulation  • Huober-Zeeb et al84
• Fertility protection in children and adolescents  • Sänger et al85
 • Sänger et al86
• Counselling and treatments in the network  • Lawrenz et al87
 • von Wolff et al88
 • von Wolff et al89
• Recommendations for fertility protection  • von Wolff et al90
 • Schüring et al91
 • von Wolff et al92
 • Dittrich et al93
*See also keyword «Fertiprotekt» in PubMed (www.ncbi.nlm.nih.gov).
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specifically address the intractable problem of fertility-preser-
vation options for young female cancer patients.94 In 2012, we 
broadened the scope of the Oncofertility Consortium to 
include the Centre for Reproductive Health After Disease, 
whose mission is to protect and preserve the reproductive 
health – including fertility, endocrine health, sexuality, or the 
ability to carry an offspring to term – of women at reproductive 
risk after disease or treatment of disease.
Structure
The multidisciplinary, international approach to the 
Oncofertility Consortium consists of research sites Oncofertility 
Professional Engagement Network (OPEN) Members, and 
key members of the multidisciplinary oncofertility team. The 
Oncofertility Consortium includes stakeholders across the 
width and depth of the academy, across departments and insti-
tutions, and includes expert core facilities and sophisticated 
human specimen collection and use and disseminates our work 
to patients, families, and the public. These are meaningful 
interactions that are fostered by the presence of a strong organ-
isation like the Oncofertility Consortium and through leader-
ship at the academic and staff level.
Centralisation of facilities. The Oncofertility Consortium Net-
work spans six continents, including 40 countries around the 
globe and 97 sites in the United States (Figure 6). The OPEN 
works to engage researchers and clinicians both domestically 
and aboard, and these communities converge at the Annual 
Oncofertility Consortium Conference held in Chicago, Illi-
nois, each year.
Continuing education. Education is a hallmark of the Oncofer-
tility Consortium’s programming. We have created numerous 
field forming and changing tools that have catalysed the growth 
of oncofertility. These items include the first comprehensive 
oncofertility textbook, training videos, and educational materi-
als that are enduring but also updatable. These products are 
listed below in more detail. In addition to these, we also house 
institutional review board (IRB) documents that can be used as 
templates for those wanting to start an oncofertility pro-
gramme, a Follicle Culture Handbook for basic scientists, and 
many other materials that enable faster adoption of best prac-
tices by members of the broader field. Through the use of Face-
book, Twitter, and other social media modalities, the 
Oncofertility Consortium facilitates the ability of our projects 
to be communicated in a way that enables the public to see how 
the work is progressing in a lay-friendly manner.
Annual Oncofertility Consortium Conference
The Oncofertility Consortium hosts an annual conference to 
convene the field and set priorities for the upcoming year. 
Oncofertility Consortium focuses on providing attendees at 
the annual Oncofertility Conference the ability to connect 
with colleagues from around the world to share research and 
clinical case studies to facilitate a rapid pace of growth within 
the field and expand resources to non-malignant conditions. 
The Oncofertility Conference is a place where the field-wide 
advances are shared through traditional lectures, hands-on 
training, and small group sessions. The variety of education 
settings address the wide range of education levels and back-
grounds represented at the conference.
Fellow Education Day Symposium
At the annual Oncofertility Conference, we host an annual 
Fellow Education Day Symposium. The purpose of the course 
is to educate fellows on fertility-preservation options and sur-
vivorship care for cancer patients across the reproductive life 
cycle. The course will also model a team approach to fertility-
preservation care. The course is comprised of didactic lectures 
given by leaders in the field interspersed with complex clinical 
cases that will be reviewed in interdisciplinary teams. 
Participants are supplementary materials for review before 
course attendance to facilitate an interactive ‘flipped classroom’ 
approach to team-based learning. This course uses e-learning 
modules that were created with the American Society for 
Reproductive Medicine (ASRM).105
Oncofertility textbooks
Together with other colleagues in the field, we have published 
seven books to encompass the areas of basic science, ethics reli-
gion and the law, medical practice, communication strategies, 
paediatric and disorders of sexual development populations, 
and non-oncologic and other non-malignant fertility threaten-
ing conditions, as well as the first of its kind Oncofertility 
Textbook, which includes didactics. The hope is these books, 
which aggregate everything we know in the field, serve as a 
starting point for material that will become integrated into the 
major oncology, internal medicine, and reproductive texts of 
our professions.
Oncofertility Saturday Academy
The Oncofertility Science Academy was created in 2007 as a 
way to introduce underserved high school girls from the 
Chicagoland area to science and medicine by engaging them in 
hands-on lab and clinical activities on the Northwestern 
University medical campus. Northwestern’s OSA programme 
impacted more than 275 students with 5 students securing 
oncofertility research internships or employment within the 
Woodruff Lab; a true example of training the next generation of 
future clinicians and scientists. The Oncofertility Saturday 
Academy (OSA) model addresses the gap in reproductive sci-
ence education at the high school level and provides an adaptable 
education model that can be implemented across multiple insti-
tutions. Currently, OSA curricula are available at Northwestern 
University; University of Pennsylvania; University of California, 
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San Diego; and Oregon National Primate Research Centre and 
has impacted 545 high school girls nationally. Learning goals of 
OSA include providing students with hands-on laboratory and 
clinical activities, incorporating art modules for learning scien-
tific and medical information in a new format and developing 
relationships with scientists, doctors, and other professionals.106
Data collection in registers
The Oncofertility Consortium does not have any formal regis-
tries or patient data collection.
Political activities
As the Oncofertility Consortium is housed within Northwestern 
University, the university policy limits lobbing activities and the 
Consortium’s ability to directly contact politicians and partici-
pate in many political activities. However, the Oncofertility 
Consortium works with other politically motivated groups, like 
the Alliance for Fertility Preservation, to push forward legisla-
tive activities in any capacity within its scope. The Oncofertility 
Consortium is the great convener in the United States and 
helps to make critical connections among members of the 
oncofertility community, like lawyers, patients, and politicians, 
to ensure that fertility-preservation coverage is attainable in 
each state. Currently, there are five states in the United States 
that require insurance companies to cover oncofertility and fer-
tility-preservation services for cancer patients.
Financial support
Most of the funding for the Oncofertility Consortium’s activi-
ties comes from the NIH and the Eunice Kennedy Shriver 
Institute for Child Health and Human Development (NIH/
NICHD). Its efforts are currently supported by the Centre for 
Reproductive Health After Disease (P50HD076188) from the 
NIH National Centre for Translational Research in 
Reproduction and Infertility (NCTRI). The annual 
Oncofertility Consortium Conference has been funded for 
years by an NIH grant (5R13HD063248), as well as institu-
tional funds from the Robert H. Lurie Comprehensive Cancer 
Centre at Northwestern University and the Office of the 
President. In addition to these funds, we have secured other 
funding from industry partners including EMD Serono, 
Merck, Ferring, Walgreens, and Reprotech Ltd. We have tar-
geted a variety of sources to enable our success and made inno-
vation and invention in communication methods a main 
mission of our programme.
Scientif ic focus
•• Mechanisms underlying the fertility threat of life-pre-
serving cancer drugs (Figure 7, Table 5).
•• Methods for cryopreservation (freezing), storing, and 
growing ovarian and gonadal tissue.
•• In vitro follicle grown and oocyte maturation using a 
three-dimensional environment.
•• Communication barriers between cancer patients and 
health care providers.
•• Ethical and legal concerns regarding the use of fertility-
preservation technologies in cancer patients.
Key points for success of the network
Because of the intrinsic value in creating diverse networks and 
collaborations, the Oncofertility Consortium continues its 
efforts to connect local centres of excellence and create a strong 
global network of diverse collaborators, many of whom may not 
have worked together otherwise. The Oncofertility Consortium 
supports interaction between global and local partners to create 
Figure 6. Decentralised structure of the oncofertility Consortium.
Purple indicates key research centres and green circles indicate oPEN members, both clinical and research sites around the globe.
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Figure 7. 10 years of transforming traditional bench science in the oncofertility Consortium network.
Table 5. Scientific focus and examples of corresponding publications with the participation of the oncofertility Consortium network.
SCIENTIFIC FoCUS ExAMPLES oF PUBLICATIoNS
• New technologies for fertility preservation and restoration  • Jakus et al107
 • Laronda et al108
 • Laronda et al109
 • Que et al110
 • Rios et al111
 • Skory et al112
 • Treff et al113
• In vitro follicle growth  • Silva et al114
 • xiao et al115
 • xiao et al116
• In vitro maturation  • Kidder117
 • Sowińska et al118
• Transplant tissue to restore reproductive and/or endocrine function  • Lunardi et al119
 • oktay and Buyuk120
 • Salama and Woodruff121
 • Smith et al122
• Create an embryo from mature follicles within the tissue  • Kizuka-Shibuya et al123
• Cryopreservation and transport protocols do not affect tissue quality nor follicle growth  • Armstrong et al124
 • Duncan et al125
 • Duncan et al126
• Individual follicles can be cryopreserved and quality assessed  • Duncan et al126
• Primary follicle number may not be a predictor of future fertility and can be cultured  • Bortoletto et al127
 • Duncan et al125
 • Finlayson et al128
 • Kniazeva et al129
 • Laronda et al130
 • Tagler et al131
(Continued)
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momentum for clinical activities (shared protocols and patient 
case studies, inclusion of allied health professionals), research 
(sharing results, both failures and successes, in ways that hasten 
work), and meeting patient needs (educational websites, patient 
decision tools, and patient navigator). By facilitating these inter-
actions, the Oncofertility Consortium ensures the coordinated 
effort of the global oncofertility community in conducting cut-
ting-edge research that can continue to be rapidly translated to 
the clinic and establish an evidence-based standard of care.
What can be further improved and further 
challenges
There are a number of common barriers that are commonly 
identified by OPEN members and the Oncofertility Consortium. 
These barriers include lack of insurance coverage and high out-
of-pocket costs for patients, lack of awareness among providers 
and patients, cultural and religious constraints, and lack of fund-
ing to help to support oncofertility programmes. Despite these 
barriers, many opportunities exist to grow the field of oncofertil-
ity. Continuing to engage stakeholders around the globe and 
expand the efforts of the Oncofertility Consortium will aid in 
the acceptance of oncofertility on a global level thus accelerating 
the pace of research from bench to bedside to babies.
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